Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations

Accepted/In Press date: 18 October 2020

e-pub ahead of print date: 30 October 2020

Published date: February 2021

Additional Information: Funding Information: We thank Professor Jan Shute (University of Portsmouth) for helpful comments on nebulised heparin. We add thanks to Dr Julian Druce, Doherty Institute, Melbourne, Australia, for donating the virus used in this study. We thank Dr Kevin Bewley, Public Health England, for designing and optimising the PRNT assay used in this study. We thank Mrs Elizabeth Penn for preparing the cell cultures, Mrs Harriet Garlant and Mrs Joanna McGlashan for technical assistance. We are grateful for receiving MERS convalescent sera from Dr Mark Page and Dr Giada Mattiuzzo, NIBSC, UK. D.S. is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). J.E.T. acknowledges the support of University of Liverpool, and M.A.S. the support of Keele University. Z.Y. acknowledges the Danish National Research Foundation (DNRF107) and the Lundbeck Foundation, Y.-H.C. the Innovation Fund Denmark and R.K. the European Commission (GlycoImaging H2020-MSCA-ITN-721297). This work was funded by Public Health England, the University of Liverpool and the University of Keele. Funding Information: We thank Professor Jan Shute (University of Portsmouth) for helpful comments on nebulised heparin. We add thanks to Dr Julian Druce, Doherty Institute, Melbourne, Australia, for donating the virus used in this study. We thank Dr Kevin Bewley, Public Health England, for designing and optimising the PRNT assay used in this study. We thank Mrs Elizabeth Penn for preparing the cell cultures, Mrs Harriet Garlant and Mrs Joanna McGlashan for technical assistance. We are grateful for receiving MERS convalescent sera from Dr Mark Page and Dr Giada Mattiuzzo, NIBSC, UK. D.S. is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). J.E.T. acknowledges the support of University of Liverpool, and M.A.S. the support of Keele University. Z.Y. acknowledges the Danish National Research Foundation (DNRF107) and the Lundbeck Foundation, Y.‐H.C. the Innovation Fund Denmark and R.K. the European Commission (GlycoImaging H2020‐MSCA‐ITN‐721297). This work was funded by Public Health England, the University of Liverpool and the University of Keele. Publisher Copyright: © 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society

Keywords: Angiotensin-Converting Enzyme 2/metabolism, Animals, Antiviral Agents/pharmacology, COVID-19/drug therapy, Chlorocebus aethiops, Heparin, Low-Molecular-Weight/pharmacology, Heparin/metabolism, Protein Binding/drug effects, SARS-CoV-2/growth & development, Spike Glycoprotein, Coronavirus/metabolism, Viral Plaque Assay

Local EPrints ID: 444485

URI: http://eprints.soton.ac.uk/id/eprint/444485

DOI: doi:10.1111/bph.15304

ISSN: 0007-1188

PURE UUID: 7cdc326e-1418-4f7f-a048-b56cb3db52f5

ORCID for Cosma Mirella Spalluto: orcid.org/0000-0001-7273-0844

ORCID for Karl J. Staples: orcid.org/0000-0003-3844-6457

Date deposited: 21 Oct 2020 16:31

Last modified: 17 Mar 2024 06:00